Georgios Tsakonas

Publications
CV
Public outreach and news

Articles

Article: PLOS ONE. 2023;18(2):e0277708

Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Makrakis D; Rounis K; Tsigkas A-P; Georgiou A; Galanakis N; Tsakonas G; Ekman S; Papadaki C; Monastirioti A; Kontogianni M; Gioulbasanis I; Mavroudis D; Agelaki S
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;24(1):193

Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature.

Tsakonas G; Koulouris A; Kazmierczak D; Botling J; Ortiz-Villalon C; Nord H; Lindskog M; Sandelin M; Micke P; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(10):2064-2078

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients.

Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Article: CANCERS. 2022;14(14):3430

Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer.

Kosibaty Z; Brustugun OT; Zwicky Eide IJ; Tsakonas G; Grundberg O; De Petris L; McGowan M; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(5):722-734

Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer.

Kaźmierczak D; Eide IJZ; Gencheva R; Lai Y; Lewensohn R; Tsakonas G; Grundberg O; de Petris L; McGowan M; Brustugun OT; Ekman S; Hydbring P
Article: LUNG CANCER. 2022;166:132-134

Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report.

Skribek M; Bozoky B; Tsakonas G
Article: LUNG CANCER. 2022;166:49-57

Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.

Killingberg KT; Halvorsen TO; Fløtten Ø; Brustugun OT; Langer SW; Nyman J; Hornslien K; Madebo T; Schytte T; Risum S; Tsakonas G; Engleson J; Grønberg BH
Article: CANCERS. 2021;13(13):3151

High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC.

Tsakonas G; Martín-Bernabé A; Rounis K; Moreno-Ruiz P; Botling J; De Petris L; Ylipää A; Mezheyeuski A; Micke P; Östman A; Ekman S
Article: ACTA ONCOLOGICA. 2021;60(3):305-311

Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc - effects and side effects.

Grozman V; Onjukka E; Wersäll P; Lax I; Tsakonas G; Nyren S; Lewensohn R; Lindberg K
Article: CANCERS. 2021;13(7):1562

Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy.

Rounis K; Skribek M; Makrakis D; De Petris L; Agelaki S; Ekman S; Tsakonas G
Article: LANCET ONCOLOGY. 2021;22(3):321-331

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.

Grønberg BH; Killingberg KT; Fløtten Ø; Brustugun OT; Hornslien K; Madebo T; Langer SW; Schytte T; Nyman J; Risum S; Tsakonas G; Engleson J; Halvorsen TO
Article: EUROPEAN JOURNAL OF CANCER. 2021;145:245-254

Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.

Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Article: CANCERS. 2020;12(12):E3707-3707

Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting.

Skribek M; Rounis K; Makrakis D; Agelaki S; Mavroudis D; De Petris L; Ekman S; Tsakonas G
Article: CLINICAL LUNG CANCER. 2020;21(6):e544-e546

Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.

Tsakonas G; Grozman V; Ekman S
Article: CANCERS. 2020;12(11):E3110-3110

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial).

Tsakonas G; Specht L; Kristensen CA; Moreno MHC; Cange HH; Soderstrom K; Friesland S
Article: CANCERS. 2020;12(7):E1804-1804

ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases.

Tsakonas G; Kamali C; De Petris L; Friesland S; Lewensohn R; Ekman S
Article: EUROPEAN JOURNAL OF CANCER. 2020;132:24-34

An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.

Tsakonas G; Lewensohn R; Botling J; Ortiz-Villalon C; Micke P; Friesland S; Nord H; Lindskog M; Sandelin M; Hydbring P; Ekman S
Article: LUNG CANCER. 2019;133:69-74

c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.

Tsakonas G; Botling J; Micke P; Rivard C; LaFleur L; Mattsson J; Boyle T; Hirsch FR; Ekman S
Article: LUNG CANCER. 2018;120:75-81

Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.

Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Article: ACTA ONCOLOGICA. 2018;57(2):231-238

Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer.

Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
Article: TUMOR BIOLOGY. 2014;35(5):4479-4488

PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.

Sooman L; Ekman S; Tsakonas G; Jaiswal A; Navani S; Edqvist P-H; Pontén F; Bergström S; Johansson M; Wu X; Blomquist E; Bergqvist M; Gullbo J; Lennartsson J
Article: INTERNATIONAL JOURNAL OF CANCER. 2014;134(7):1751-1757

Cancer incidence and mortality patterns in women with anorexia nervosa.

Karamanis G; Skalkidou A; Tsakonas G; Brandt L; Ekbom A; Ekselius L; Papadopoulos FC
Article: MEDICAL ONCOLOGY. 2013;30(3):638

Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.

Sooman L; Lennartsson J; Gullbo J; Bergqvist M; Tsakonas G; Johansson F; Edqvist P-H; Pontén F; Jaiswal A; Navani S; Alafuzoff I; Popova S; Blomquist E; Ekman S
Show more

All other publications

Review: JOURNAL OF INTERNAL MEDICINE. 2022;291(6):732-754

Complications following novel therapies for non-small cell lung cancer.

Skribek M; Rounis K; Tsakonas G; Ekman S
Review: CLINICAL RHEUMATOLOGY. 2021;40(5):1687-1695

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?

Chatzidionysiou K; Liapi M; Tsakonas G; Gunnarsson I; Catrina A
KI thesis / dissertation: 2020

Biomarkers for CNS metastasis in non-small cell lung cancer (NSCLC)

Tsakonas, Georgios
Review: EUROPEAN JOURNAL OF CANCER. 2020;125:1-11

Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?

Califano R; Gomes F; Ackermann CJ; Rafee S; Tsakonas G; Ekman S
Corrigendum: LUNG CANCER. 2018;123:178-179

Corrigendum to "Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden" [Lung Cancer 120 (June) (2018) 75-81].

Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Review: JOURNAL OF THORACIC DISEASE. 2018;10(Suppl 13):S1547-S1555

Oncogene-addicted non-small cell lung cancer and immunotherapy.

Tsakonas G; Ekman S
Review: CANCER TREATMENT REVIEWS. 2017;54:122-131

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.

Tsakonas G; De Petris L; Ekman S

Employments

Postdoctoral Studies, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2020

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI